PubMed

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

Ahrén B, Gomis R, Standl E, Mills D, Schweizer A.

Diabetes Care. 2004 Dec;27(12):2874-80.PMID: 15562200 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Ahrén B, Pacini G, Foley JE, Schweizer A.

Diabetes Care. 2005 Aug;28(8):1936-40.PMID: 16043735 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):166-74.PMID: 17300592 [PubMed - indexed for MEDLINE]Related articles

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.

Diabetes Care. 2007 Apr;30(4):890-5. Epub 2007 Feb 2.PMID: 17277036 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D.

Horm Metab Res. 2006 Jun;38(6):423-8.PMID: 16823726 [PubMed - indexed for MEDLINE]Related articles

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.

Diabetes Obes Metab. 2008 Aug;10(8):675-82. Epub 2007 Nov 22.PMID: 18248490 [PubMed - indexed for MEDLINE]Related articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

Horton ES, Foley JE, Shen SG, Baron MA.

Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. Epub 2008 Feb 18.PMID: 18284434 [PubMed - indexed for MEDLINE]Related articles

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.

Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.

Horm Metab Res. 2007 Nov;39(11):826-9.PMID: 17992639 [PubMed - indexed for MEDLINE]Related articles

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.

Ristic S, Byiers S, Foley J, Holmes D.

Diabetes Obes Metab. 2005 Nov;7(6):692-8.PMID: 16219012 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S.

Horm Metab Res. 2008 Dec;40(12):892-5. Epub 2008 Aug 22.PMID: 18726829 [PubMed - indexed for MEDLINE]Related articles

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.

Diabetes Obes Metab. 2007 Mar;9(2):186-93.PMID: 17300594 [PubMed - indexed for MEDLINE]Related articles

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.

Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.

Diabetologia. 2007 Jun;50(6):1148-55. Epub 2007 Mar 27.PMID: 17387446 [PubMed - indexed for MEDLINE]Related articles

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE.

Diabetes Obes Metab. 2008 Nov;10(11):1114-24. Epub 2008 Mar 18.PMID: 18355325 [PubMed - indexed for MEDLINE]Related articles